CDXS: biocatalysis returns to growth as annual guidance holds
CDXS reported $19.3M in third-quarter revenue, with biocatalysis growing again and full-year revenue guidance kept at $72M–$76M. Source: TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, CDXS posted third-quarter revenue of $19.3 million. The biocatalysis business has returned to growth, and the company has kept its full-year revenue guidance in the range of $72 million to $76 million.
The ECO Synthesis platform reached the 100-gram scale, and more new customer evaluations have moved forward. Following a financing deal, the stated cash runway now extends through 2028.
why it matters
For investors, the news matters mainly for the company itself: a return to growth in biocatalysis and unchanged guidance ease concerns about meeting the annual plan, while a longer cash runway reduces near-term funding risk.
market impact
CDXS: results and unchanged guidance affect the company's own shares, with no broad market effect
tags
instruments
sources
- CDXS: Biocatalysis growth and ECO Synthesis scale-up advanced alongside maintained FY guidance — TradingView, 12 November 2026 at 23:09 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗